Vasoactive intestinal peptide (VIP, aviptadil) clinical trials: 6 trials
Page 1 of 1
Read 6 Vasoactive intestinal peptide (VIP, aviptadil) clinical trials with posted results or linked papers with results in PepBank.
- ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
NCT04843761 · Phase 3 · Completed
Posted results
- Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
NCT06729606 · Phase 3 · Completed
Posted results
- Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure
NCT04311697 · Phase 2/3 · Completed
Posted results
- A Clinical Study Evaluating Inhaled Aviptadil on COVID-19
NCT04844580 · Phase 2 · Completed
Linked paper with results
- The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) in Episodic Migraine Patients
NCT04260035 · Not applicable · Completed
Linked paper with results
- The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) on Headache, Cranial Hemodynamic and Autonomic Symptoms in Healthy Volunteers
NCT03989817 · Not applicable · Completed
Linked paper with results